{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":23,"n_cols":5,"rows_kept":23,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[10,2,10,3],[15,2,15,3],[16,2,16,3],[20,2,20,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910298336303321"]
[null,null,"Titolo",null,"Novel Technologies for Vaccine Development / / edited by Igor S Lukashevich, Haval Shirwan"]
[null,null,"Pubbl/distr/stampa",null,"Vienna : , : Springer Vienna : , : Imprint : Springer, , 2014"]
[null,null,"ISBN",null,"3-7091-1818-2"]
[null,null,"Edizione",null,"[1st ed. 2014.]"]
[null,null,"Descrizione fisica",null,"1 online resource (393 p.)"]
[null,null,"Disciplina",null,"610"]
[{"$nulls":4},"615.19"]
[{"$nulls":4},"615372"]
[{"$nulls":4},"616079"]
[null,null,"Soggetti",null,"Vaccines"]
[{"$nulls":4},"Pharmaceutical technology"]
[{"$nulls":4},"Immunology"]
[{"$nulls":4},"Vaccine"]
[{"$nulls":4},"Pharmaceutical Sciences/Technology"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references at the end of each chapters."]
[null,null,"Nota di contenuto",null,"Reverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines -- Viral-Vectored Vaccines to Control Pathogenic Filoviruses -- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention -- Current Status and Future of Polio Vaccines and Vaccination -- Current Status of Hantavirus Vaccines Development -- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses -- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines -- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines -- Radiovirotherapy for the Treatment of Cancer -- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer -- The Use of Oncolytic Herpesvirus for the Treatment of Cancer -- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines."]
[null,null,null,"Sommario/riassunto","This book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer "]
[{"$nulls":4},"vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a “must read” for all those involved in vaccine development, both in academia and industrial vaccine development."]